Recent changes to US prescription drug pricing, such as the introduction of Most Favored Nation and recent manufacturer agreements, have created a new environment for patient access.
Our whitepaper explores how sponsors can adapt to this environment. We share practical guidance on how you can meet the standard without overstepping FDA limits and aligning direct-to-consumer (DTC) advertising with approved labeling.
Fill out the form on the right to download the whitepaper.
"*" indicates required fields
